[
  {
    "ts": null,
    "headline": "Novo obesity data positive for Eli Lilly and Amgen, says UBS",
    "summary": "UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also",
    "url": "https://finnhub.io/api/news?id=7daf6f13d49aa39a0fb0bd1707c87219e5838015a83bb866ad16198c58c11208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734784243,
      "headline": "Novo obesity data positive for Eli Lilly and Amgen, says UBS",
      "id": 132095943,
      "image": "https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also",
      "url": "https://finnhub.io/api/news?id=7daf6f13d49aa39a0fb0bd1707c87219e5838015a83bb866ad16198c58c11208"
    }
  }
]